TipHub

₹381.75

▼ -0.92 -0.24%

As of 21 Sept 2026 · delayed

NSE Listed · Healthcare

Panacea Biotec Limited (PANACEABIO)

Volume: 53,94352W Range:₹292.4₹647
NSE BSE www.panaceabiotec.com AI Report
Key Ratios
Checked 3h ago
Market Cap₹2,350 Cr
Current Price₹381.75
Previous Close₹382.67
High / Low (52w)₹647 / ₹292.4
Volume53,943
Avg Vol (1W)—
Avg Vol (1M)—
Stock P/E4,955.63
Book Value₹128.44
Dividend Yield0%
ROE-292.75%
ROA-70.67%
Revenue (TTM)—
Revenue Growth—
Profit Margin—
Total Debt₹15 Cr
Shares Outstanding6 Cr
Face Value₹1
EPS (TTM)₹-1.17
P/B2.99
Debt / Equity2.85
50 DMA₹419.61
200 DMA₹402.59
Day change-0.24%
Price Chart
₹381.75▼ 6.28% · 1Y
₹608₹2961.7Cr
2025-09-24
2026-09-21

20-day avg volume: 1.0L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 24% YoY.
Cons
  • Company is loss-making at the latest annual result.
  • Stock trades at a high P/E of 4956.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹147 Cr₹163 Cr₹133 Cr₹167 Cr₹141 Cr₹165 Cr₹167 Cr₹200 Cr
EBITDA₹3 Cr₹3 Cr₹-27 Cr₹-4 Cr₹-20 Cr₹6 Cr₹-3 Cr₹2 Cr
Net Profit₹5 Cr₹5 Cr₹-2 Cr₹4 Cr₹-14 Cr₹4 Cr₹1 Cr₹2 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹580 Cr₹68 Cr₹112 Cr₹91 Cr₹99 Cr₹111 Cr₹657 Cr₹135 Cr
EBITDA₹-40 Cr₹-17 Cr₹-3 Cr₹-15 Cr₹-2 Cr₹2 Cr₹-21 Cr₹9 Cr
Net Profit₹-8 Cr₹-12 Cr₹-7 Cr₹-16 Cr₹-7 Cr₹0 Cr₹-5 Cr₹1 Cr
EPS-1.37—————-0.88—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹1,376 Cr₹1,390 Cr₹1,178 Cr₹1,759 Cr₹1,271 Cr₹1,241 Cr₹1,290 Cr₹1,262 Cr
Total Liabilities₹1,028 Cr₹1,195 Cr₹1,409 Cr₹885 Cr₹431 Cr₹402 Cr₹459 Cr₹433 Cr
Equity₹347 Cr₹196 Cr₹-232 Cr₹874 Cr₹840 Cr₹838 Cr₹831 Cr₹829 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹103 Cr₹-22 Cr₹108 Cr₹295 Cr₹-420 Cr₹2 Cr₹-26 Cr₹23 Cr
Investing₹-5 Cr₹-35 Cr₹-48 Cr₹1,283 Cr₹430 Cr₹10 Cr₹65 Cr₹-40 Cr
Financing₹-101 Cr₹91 Cr₹-47 Cr₹-1,176 Cr₹-18 Cr₹-3 Cr₹-3 Cr₹-1 Cr
Free Cash Flow₹103 Cr₹-22 Cr₹108 Cr₹295 Cr₹-420 Cr₹2 Cr₹-26 Cr₹23 Cr
Shareholding
Promoter 75.82% Institutions 0.16% Public 24.02%
About Panacea Biotec Limited

Healthcare · Biotechnology

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

www.panaceabiotec.com ↗
Efficiency & Working Capital
ROCE-2.4%
Interest Coverage-3.4
Dividend Payout—
Debtor Days42 d
Inventory Days110 d
Payable Days108 d
Cash Conversion Cycle44 d
Working Capital Days152 d
Shareholding Details

As of 2026-06-30

Promoter72.5%
FII2.3%
DII2.3%
Institutions4.6%
Public23%
Promoter Pledge0%
No. of Shareholders33,532
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters73.6%73.6%73.6%73.5%72.9%72.5%72.5%72.5%72.5%72.5%72.5%72.5%
FIIs0.3%0.3%0.3%0.3%0.4%0.4%1.2%0.8%1.1%1.4%1.6%2.3%
DIIs0%0%0.8%1.1%1.2%1.2%1.5%1.5%1.8%1.9%2%2.3%
Public26.1%26.1%25.3%25.2%25.6%26%24.9%25.2%24.7%24.3%24%23%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders48,87847,09146,24245,51339,98235,44633,59334,25633,59334,59732,62033,532
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Dr. Rajesh JainShareholding of Promoter and Promoter Group49%3.00 Cr
Mr. Sandeep JainShareholding of Promoter and Promoter Group15.3%93,51,924
Mrs. Nirmala JainShareholding of Promoter and Promoter Group4.1%25,11,000
First Lucre Partnership Co.Shareholding of Promoter and Promoter Group3.7%22,55,815
Massachusetts Institute Of TechnologyPublic Shareholding1.7%10,50,000
Viral Amal ParikhPublic Shareholding1.5%8,99,341
Rajesh Jain (huf) (karta : Rajesh Jain)Shareholding of Promoter and Promoter Group0.3%2,00,000
Second Lucre Partnership Co.Shareholding of Promoter and Promoter Group0.1%57,639
Sandeep Jain (huf) (karta : Sandeep Jain)Shareholding of Promoter and Promoter Group0%0
Mr. Abhey Kumar JainShareholding of Promoter and Promoter Group0%0
Mr. Ashish JainShareholding of Promoter and Promoter Group0%500
Mrs. Meena JainShareholding of Promoter and Promoter Group0%0
Mrs. Pamilla JainShareholding of Promoter and Promoter Group0%0
Mr. Ankesh JainShareholding of Promoter and Promoter Group0%0
Mr. Harshet JainShareholding of Promoter and Promoter Group0%0
Mrs. Priyanka JainShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Rajesh JainChairman / Executive Director / M D / Promoter2025
Sandeep JainED / Joint MD / Promoter2025
Ankesh JainWTD & Executive Director2025
Harshet JainWTD & Executive Director2025
Sanjay TrehanExecutive Director / WTD - Technical2025
Ambika SharmaIndependent Non Exe. Director2025
Krishan Kumar JalanIndependent Non Exe. Director2025
Rajesh JainIndependent Non Exe. Director2025
Rajender Pal SinghIndependent Non Exe. Director2025
Venkatesh SarvasiddhiIndependent Non Exe. Director2025
Vinod GoelCS / Compliance Officer / Group CFO / Head - Legal2025
Segments — Product
SegmentRevenueShare
Vaccines₹96 Cr21.7%
Formulations₹348 Cr78.3%
Research and Development₹0 Cr0%
Segments — Geography
RegionRevenueShare
Domestic₹79 Cr82.3%
Overseas₹17 Cr17.7%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹11366
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-13Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20253880060394
20252300000230
20251440060150
Insider / Designated-Person Trades

4 recent disclosure(s)

Nosheen SheikhDisposal · 3,000
Dr. Rajesh JainDisposal · 2,00,000
Rajesh Jain HUFAcquisition · 2,00,000
Nosheen SheikhAcquisition · 3,000
Substantial Acquisitions (SAST)

1 disclosure(s)

NULL12/06/2026 · 2,00,000
Company Information
Incorporated1984
ChairmanRajesh Jain
AuditorSuresh Surana & Associates LLP/R & D
Investor Email[email protected]; investorgrievances@pa
🌐 www.panaceabiotec.com ↗

📍 Ambala-Chandigarh Highway, Lalru, Punjab, 140501

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Pacific Industries Ltd.Page Industries Ltd.Paisalo Digital LimitedPakka LimitedPalash Securities Ltd.Palred Technologies Ltd.Panache Digilife LimitedPanama Petrochem Ltd.Panchmahal Steel Ltd.Panorama Studios International Ltd.Pansari Developers Ltd.Par Drugs & Chemicals Ltd.All “P” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search